Hostname: page-component-54dcc4c588-rz4zl Total loading time: 0 Render date: 2025-10-02T07:10:35.836Z Has data issue: false hasContentIssue false

Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial: commentary, Baldwin et al

Published online by Cambridge University Press:  19 August 2025

David S. Baldwin*
Affiliation:
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK
Nathan T. M. Huneke
Affiliation:
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK
*
Correspondence: David S. Baldwin. Email: dsb1@soton.ac.uk

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Commentary
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

He, Y, Polymeropoulos, C, Mohrman, M, Truslow, S, Xiao, C, Wu, Y, et al. Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial. Br J Psychiatry 2025; 9: 18.Google Scholar
Lee, CH, Hung, SY. Physiologic functions and therapeutic applications of α7 nicotinic ACh receptor in brain disorder. Pharmaceutics 2022; 15: 31.10.3390/pharmaceutics15010031CrossRefGoogle Scholar
Feuerbach, D, Pezous, N, Weiss, M, Shakeri-Nejad, K, Lingenhoehl, K, Hoyer, D I, et al. AQW 051, a novel, potent and selective α 7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol 2015; 172: 1292–304.10.1111/bph.13001CrossRefGoogle Scholar
Hampsey, E, Perkins, A, Young, AH. BNC210: an investigational α7-nicotinic ACh receptor modulator for the treatment of anxiety disorders. Exp Opin Investig Drugs 2023; 32: 277–82.10.1080/13543784.2023.2192922CrossRefGoogle ScholarPubMed
Labuschagne, I, Grace, C, Rendell, P, Terrett, G, Heinrichs, M. An introductory guide to conducting the Trier Social Stress Test. Neurosci Biobehav Rev 2019; 107: 686–95.CrossRefGoogle ScholarPubMed
Huneke, NTM, Rowlatt, H, Hyde, J, McEwan, A, Maryan, L, Baldwin, DS, et al. A novel procedure to investigate social anxiety using videoconferencing software: a proof-of-concept study. Psych Res 2022; 316: 114770.10.1016/j.psychres.2022.114770CrossRefGoogle ScholarPubMed
Saint, SA, Moscovitch, DA. Effects of mask-wearing on social anxiety: an exploratory review. Anxiety Stress Coping 2021; 34: 487502.CrossRefGoogle ScholarPubMed
von Majewski, K, Kraus, O, Rhein, C, Lieb, M, Erim, Y, Rohleder, N. Acute stress responses of autonomous nervous system, HPA axis, and inflammatory system in posttraumatic stress disorder. Transl Psychiatry 2023; 13: 36.CrossRefGoogle ScholarPubMed
Tomasi, J, Zai, CC, Pouget, JG, Tiwari, AK, Kennedy, JL. Heart rate variability: evaluating a potential biomarker of anxiety disorders. Psychophysiology 2024; 61: e14481.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.